Article Text

PDF
Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy
  1. Won Bin Cho,
  2. Jun Woong Moon,
  3. Hyung Chan Kim
  1. Department of Ophthalmology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Republic of Korea
  1. Correspondece to Dr Hyung Chan Kim, Department of Ophthalmology, Konkuk University Medical Center, Konkuk University School of Medicine, #4-12 Hwayang-dong, Gwangjin-gu, Seoul, Republic of Korea, 143-729; eyekim{at}kuh.ac.kr

Abstract

Background/aims To evaluate efficacy of intravitreal triamcinolone (IVTA) and bevacizumab (IVB) as adjunctive treatments to panretinal photocoagulation (PRP).

Methods In 91 eyes of 76 patients (clinically significant macular oedema (CSME) 46 eyes; no CSME 45 eyes) with severe diabetic retinopathy, PRP with IVTA (IVTA group, 30 eyes) or PRP with IVB (IVB group, 31 eyes) or PRP only (PRP group, 30 eyes) was performed. Primary outcome measures were changes in best corrected visual acuity (BCVA) and central macular thickness (CMT) at 1 and 3 months. Secondary outcome measures were proportion of visual gain or loss, and decreased or increased CMT.

Results There was significant worsening in BCVA from 0.26 to 0.29 at 1 and 3 months (p=0.031) in the PRP group. In eyes with CSME, there was significant improvement of BCVA from 0.33 to 0.27 at 1 and 3 months (p=0.012) in IVTA group. In eyes without CSME, PRP group showed significant worsening in BCVA from 0.18 to 0.26 at 1 month (p=0.008) and 0.27 at 3 months (p=0.005). There was significant improvement in CMT in IVTA and IVB groups: in eyes without CSME, there was significant increase in CMT from 209.75 to 259.00 μm at 1 month (p=0.023) and to 276.14 μm at 3 months (p=0.011) in the PRP group; in eyes with CSME, the proportion of eyes with visual gain and decreased CMT was significantly higher in the IVTA group (75% and 100%, respectively) than in the IVB group (37.5% and 62.5%, respectively).

Conclusions IVTA and IVB may be effective adjunctive treatments to PRP, minimising the risk of PRP-induced macular oedema and visual loss.

  • Intravitreal bevacizumab
  • intravitreal triamcinolone acetonide
  • macular oedema
  • panretinal photocoagulation

Statistics from Altmetric.com

Footnotes

  • Funding The authors have no financial interest in any aspect of this study.

  • Competing interests None.

  • Ethics approval This study was conducted with the approval of the Ethical Committee of Konkuk University College of Medicine. The study followed the tenets of the Declaration of Helsinki.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.